[Comment] Treatment concentration of high-sensitivity C-reactive protein

13:56 EST 13 Nov 2017 | The Lancet

The landmark CANTOS trial evaluated the use of canakinumab, a monoclonal antibody targeting interleukin 1β, in 10 061 patients with previous myocardial infarction who had high-sensitivity C-reactive protein (hsCRP) concentrations of 2 mg/L or higher.1 Interleukin 1β has multiple potential mechanisms that contribute to the pathogenesis of atherothrombotic cardiovascular disease.2 Induction of interleukin 6 leads to the release of acute phase reactants including hsCRP. Thus, hsCRP serves as a surrogate marker of the overall inflammatory milieu,2 often in situations where patients have multiple co-morbidities,3 with a cumulative dose-response indicating a higher risk.

Original Article: [Comment] Treatment concentration of high-sensitivity C-reactive protein


More From BioPortfolio on "[Comment] Treatment concentration of high-sensitivity C-reactive protein"

Quick Search


Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...